English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The present investigation was to study the clinical efficacy of the substrate antihypoxantQantioxidant Reamberin used in the correction of tissue hypoxia and free radical oxidation (FRO) in patients with severe blood loss of ulcerous etiology. The paper presents the results of the investigation of Reamberin used in the therapy of posthemorrhagic hypoxia, by simulQ taneously evaluating metabolism and the parameters of lipid peroxidation (LPO) and the antioxidative system (AOS) in patients with ulcerative gastroduodenal hemorrhage (UGDH). Materials and methods. ThirtyQsix patients with UGDH with a circulating blood volume (CBV) deficit of 30—40% and a globular volume of 50—60% were examined. Systemic hemodynamics was examined by the integral body theography method by means of a Diamant rheoanalyzer. The values of blood oxygenQtransport function were determined and calculated. For rapid expression and evaluation of the summary state of FRO, a procedure for the recording of activated H2O2 chemiluminescence was used in the presence of Fe 2+ . Metabolic disturbances were judged from the concentration of lactate and glucose. Results. Acute blood loss of ulcerous etiology has been found to cause significant systemic hemodynamic and microcirculatory disorders and impairments of metabolism, oxyQ gen balance, and tissue perfusion and to intensify FRO and LPO processes, and the use of 1.5% Reamberin in a volume of 800 ml/day substantially reduces the degree of specific cell metabolic disturbances in critical conditions, such as tissue hypoxia, mitochondrial dysfunction, FRO activation, LPOQAOS imbalance. Conclusion. Inclusion of Reamberin in the intensive care of acute blood loss diminishes the manifestations of tissue hypoxia and improves oxygen delivery and conQ sumption. The agent activates the antioxidative system, inhibits LPO processes in the ischemic tissues, and reduces the

Correction of Hypoxia and Free Radical Oxidation Processes in Gastroduodenal Hemorrhages